Clinical Research Nursing Scopes and Standards Open for Comment
Document Open for Comment
The International Association of Clinical Research Nurses (IACRN) is seeking professional and public input on the first scope and standards of practice for the specialty practice of Clinical Research Nursing. The document, Scope and Standards of Practice for Clinical Research Nursing, was formally presented at the 7th annual IACRN conference, in Baltimore, MD on October 15, 2015. The document is currently open for public comments at http://iacrn.memberlodge.org/
The newly released draft document establishes formal direction for the clinical research nurse around the following definition: Clinical Research Nursing is the specialized practice of professional nursing focused on maintaining equilibrium between care of the research participant and fidelity to the research protocol. This specialty practice incorporates human subject protection; care coordination and continuity; contribution to clinical science; clinical practice; and study management throughout a variety of professional roles, practice settings, and clinical specialties.
IACRN has clinical research nurse representation from 34 states, as well as in Great Britain, Australia, Canada, China, Ireland, Israel, Japan, Spain, Switzerland, and Taiwan. For more information, see the IACRN website listed above.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
